Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.

Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. - 3/13/2009

Home

Index of Filings

News and Press Releases

Filings

Decisions

Settlements

Litigation Activity Indices

Top Ten List

Annual/Quarterly Updates

Clearinghouse Research

Articles & Papers

Search

Related Sites

About Us

Local Rules

Sponsors

Register

_______________
Copyright © 2001
Stanford Law School

2009 News and Press Releases

SEARCH

News	News 2009
HEADLINES \| SETTLEMENTS AND DISMISSALS \| COURT FILINGS LINKS TO OTHER NEWS \| NEWS ARCHIVE	HEADLINES ARCHIVED SETTLEMENTS AND DISMISSALS ARCHIVED

SETTLEMENT NEWS:

Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
Staff Writer

PR Newswire. March 13, 2009
_________________________________________________________________________

EXCERPT: If you purchased the securities of Schering-Plough Corporation during the period from May 9, 2000 through and including February 15, 2001 (the "Class Period"), then you could receive a payment from the proposed settlement of this securities class action. A Settlement has been proposed in a class action concerning the price of Schering-Plough securities during the Class Period. The Settlement will provide a settlement fund of one hundred and sixty-five million dollars($165,000,000) for the benefit of investors who purchased Schering-Plough securities during the Class Period. If you qualify, you may send in a claim form to get benefits. The United States District Court for the District of New Jersey authorized this Summary Notice. Before any money is paid to Class Members, the Court will hold a hearing to decide whether to approve the Settlement. […] What is this Lawsuit About? Lead Plaintiff, on behalf of the Class, alleges that the Defendants knowingly or recklessly made false and misleading statements and omissions that failed adequately to disclose serious and widespread deficiencies in Schering-Plough's manufacturing and quality operations and that such deficiencies gave rise to a serious risk that the United States Food and Drug Administration would delay approval of the company's New Drug Application for an allergy drug known as Clarinex(R).

Back to News page | Back to Archived News 2009 page | Back to Top

�